5 questions facing emerging biotech in 2025

Young drugmakers confront several harsh realities this year, among them a contracting sector and competition from China.

Tune raises $175M for hepatitis B medicine, epigenetic research

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat chronic hepatitis B infections.

Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku

Nippon Shinyaku will pay Regenxbio $110 million upfront for U.S. and Asia rights to treatments for Hunter and Hurler syndromes.

Intellia to stop work on rare disease therapy, lay off staff

The CRISPR company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.

J&J files a potential blockbuster; Lykos shakes up its board

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong revenue numbers, while Bausch + Lomb made an acquisition.

Sana Biotetechnology diabetes results generates guarded optimism

Bayer moves allogeneic cell therapy into phase 3 Parkinson’s trial

Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy